智通财经网·2025-09-15 09:44Core Viewpoint - Shanghai Pharmaceuticals (02607) announced that its controlling shareholder, Shanghai Industrial (Group) Co., Ltd., plans to increase its stake in the company through its wholly-owned subsidiary, Shanghai International Investment Co., Ltd. [1] Group 1: Shareholding Increase - Shanghai International Investment Co., Ltd. increased its holdings by 100,000 H-shares on September 15, 2025, bringing its total to 301 million H-shares, which represents 8.104% of the company's total share capital [1] - The controlling shareholder plans to acquire an additional 55 million to 74 million H-shares over the next 12 months, not exceeding 2% of the company's voting shares [1] - The share purchase will be conducted through the Hong Kong Stock Exchange via a centralized bidding method, with no fixed price range set for the acquisitions [1] Group 2: Funding and Strategy - The funding for the share purchases will come from the own funds of Shanghai International Investment Co., Ltd. [1] - The company expresses confidence in its future development, which underpins the decision to increase its shareholding [1]